Bethesda, Md., June 27, 2023 – The complexity of manufacturing new biologics and next gen medicines demands experience, advanced technologies and excellence in performance management. Precision’s acquisition of Baseline Controls combined with the expertise of Project Farma provides an end-to-end scope of manufacturing solutions for life-science companies.

Read the press release

Precision for Medicine, a leading biomarker-driven clinical research organization (CRO), received wide recognition at the prestigious 2023 CRO Leadership Awards. The awards acknowledge top CRO partners and are determined by feedback from pharma and biotech sponsors. Precision has been honored in all five categories: Capabilities, Compatibility, Expertise, Quality, and Reliability, securing awards in the Overall, Big Pharma, and Small Pharma categories, along with several distinguished Champion Awards. 

This recognition serves as a testament to our commitment to quality and our clients’ trust in delivering measurable results. 

Read Press Release > 

Bethesda, Md., April 26, 2023 — Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointments of Stacey Hanna, General Counsel and Chief Compliance Officer, and Tina Durocher-Murphy, Chief People Officer. In these roles, Stacey and Tina are responsible for all legal and compliance and human resources functions, respectively, across the enterprise. Both leaders will report directly to Mark Clein, Chief Executive Officer of Precision Medicine Group.

“As Precision Medicine Group innovates and evolves, adding senior-level talent like Tina and Stacey contributes significantly to scaling people, process, and culture for our next phase of growth,” said Clein. “Stacey and Tina are experienced leaders who have proven track records to ensure that our people and processes are well connected to and supported for our growth trajectory.”

(more…)

BETHESDA, MD, March 14, 2023 – Precision Medicine Group (PMG), a leading next-generation provider of drug development and commercialization services, today announced the appointment of John Hubbard, PhD, as Chairman of its Board of Directors.

“We are thrilled to welcome John to our Board. He is a highly regarded leader in the pharmaceutical industry with extensive experience in clinical development and operations, strategic planning and business development,” said Mark Clein, Chief Executive Officer of Precision Medicine Group. “His impressive qualifications make him uniquely qualified to appreciate the breadth of services offered across our organization and to provide valuable insight as we continue to expand our global footprint and integrated capabilities.”

(more…)

Stern IR, part of Precision Value & Health, enhances market leadership position by integrating IR expertise, deep biotech knowledge, and ESG solutions to bring substantive value to clients. ESG Expert Molly Podolefsky, PhD, to lead complementary new ESG capability

NEW YORK, March 2, 2023 — Stern IR, Inc., a Precision Value & Health company, today announced the launch of its new environmental, social, and governance (ESG) advisory practice. The addition of the ESG practice will deliver a suite of solutions, including materiality assessments, ESG strategy and roadmap development, reporting, and communications packages that are well integrated with Stern’s core investor relations (IR) competencies. These complementary ESG solutions are designed to meet the evolving IR needs of biotechnology and healthcare companies, which increasingly involve and are influenced by ESG considerations and factors with ESG rapidly becoming a core component of best-in-class IR.

(more…)

QuartzBio’s suite of end-to-end SaaS solutions provides pharmaceutical and biotech clients with a fully connected data ecosystem linking sample, biomarker, and clinical data to improve collaboration, planning and R&D productivity.

[Frederick, MD – January 24, 2023] Precision for Medicine, the first global, precision medicine clinical research services organization, today announced the strategic acquisition of SolveBio by QuartzBio.

SolveBio’s intelligent technologies and enterprise data management platform has integrated into QuartzBio’s suite of SaaS solutions, providing a single, scalable solution supporting clinical sample inventory management and biomarker data management for the biotech and pharmaceutical sectors.

(more…)